|
''Lawrence Friedhoff'', MD, PhD, FACP, is the Chief Development Officer of Axovant Sciences, Ltd. and the Senior Vice President, Research & Development at Roivant Sciences, Inc. Friedhoff has led teams that developed and obtained approval for six new drugs, including Aricept (donepezil), the most widely used drug for the treatment of Alzheimer’s disease, and Aciphex (rabeprazole) for the treatment of heartburn. Each is prescribed to millions of patients around the world. Friedhoff has worked in pharmaceutical R&D for more than 30 years. He previously held leadership positions at Eisai, Squibb, and Andrx and also has been part of entrepreneurial ventures and academic-based research teams. In each of these roles, he has held primary responsibility for choosing novel drug candidates, preparing comprehensive plans for their development, and managing all phases of that development. All of the completed pivotal trials he has led from inception to conclusion have resulted in successful drug approvals. Friedhoff is the author of ''New Drugs: An Insider’s Guide to the FDA Approval Process for Scientists, Investors, and Patients'', and has authored and co-authored numerous articles for peer-reviewed publications. He holds an MD from New York University, a PhD in Chemistry from Columbia University, and is a Fellow of the American College of Physicians.〔(【引用サイトリンク】url=http://www.bloomberg.com/research/stocks/private/person.asp?personId=54289178&privcapId=300902827 )〕 ==Bibliography== Friedhoff, Lawrence T. New Drugs: An Insider's Guide to the Fda's New Drug Approval Process, for Scientists, Investors, and Patients. New York: Pharmaceutical Special Projects Group, 2009. ISBN 9781419699610 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「Lawrence Friedhoff (doctor)」の詳細全文を読む スポンサード リンク
|